FDAsafety guidance66% confidence
Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Marksans Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Gastroenterology · Proton Pump Inhibitor
- Sub-indication
- General
Related signal: FDA Accepts ANDA for Esomeprazole Magnesium by Marksans Pharma